Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
A phase 2 trial of ST-1898 tablets in thyroid cancer, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.
Overview
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer is a phase 2 interventional study registered as NCT06359847 by Beijing Scitech-Mq Pharmaceuticals Limited, with 60 participants planned, started 2023-11-15 and due to reach its primary completion in 2027-12. Interventions recorded: ST-1898 tablets.
Setting
A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy
Phase
Phase 2
Sponsor
Beijing Scitech-Mq Pharmaceuticals Limited
Registry
Enrolled
60 enrolled
Similar pages
not linked directly; found by shared links- AgentAL2846
Shares Thyroid cancer and the tag pipeline.